Penn Pharma Invests in Manufacturing Capacity

Penn Pharma has announced its plans to invest in additional tablet manufacturing and coating capacity to meet customer demand.  This investment is in addition to the £14 million ($21.2 million) recently invested in a solid dose contained manufacturing facility to handle potent active pharmaceutical ingredients.  
  
The new £3 million ($4.5 million) investment follows the recent completion of Penn Pharma’s new 15,000-ft² site for the clinical and commercial manufacture of tablets and capsules.

Penn Pharma has been providing pharmaceutical services for more than 30 years and employs 275 staff on its two sites in South Wales, UK.